Atossa Therapeutics, Inc.ATOSNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -0.02% | +1.05% | +3.07% | +2.73% | +2.70% |
| Weighted Average Shares Diluted Growth | -0.02% | +1.05% | +3.07% | +2.73% | +2.70% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | -100.00% | -100.00% | +217.35% | +0.00% |
| Asset Growth | -21.85% | -20.58% | -22.33% | -24.86% | -27.01% |
| Book Value per Share Growth | -25.00% | -22.28% | -26.10% | -29.94% | -34.21% |
| Debt Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | -23.62% | -39.81% | +10.91% | +54.86% | +57.39% |
| SG&A Expenses Growth | -0.93% | +11.85% | +0.93% | -0.39% | +30.41% |